Comprehensive analysis of chromosome 1p deletions in neuroblastoma.

Published

Conference Paper

BACKGROUND: Chromosome 1p deletions are common in advanced neuroblastomas, but the biological and clinical implications of this clonal rearrangement remain controversial. Previous studies of chromosome 1p loss of heterozygosity (LOH) have been limited by analyses of relatively small number of tumors derived from heterogeneously assessed and treated patient populations. Therefore, a strictly representative cohort of 288 Children's Cancer Group neuroblastoma patients treated on the most recent phase III therapeutic trials was identified. PROCEDURE: Primary tumors from these patients were analyzed for LOH at precisely mapped and highly informative 1p polymorphic loci located from 1p32 to 1p36.3 by multiplex PCR. RESULTS: Ninety-three primary tumor specimens (32%) had LOH at multiple 1p36 marker loci. All 1p deletions overlapped the previously determined smallest region of overlap (SRO). One tumor had a small terminal deletion completely within 1p36.3, allowing for further refinement of the 1p36 SRO. We found no evidence to support an additional, nonoverlapping region of LOH within 1p32-36. We confirmed the strong correlation of 1p36 LOH with MYCN amplification (P < 0.001), advanced disease stage (P < 0.001), and decreased both 3-year event-free survival and overall survival probabilities (P< 0.001). When stratified for MYCN amplification status or entered into a multivariate analysis, 1p36 LOH remained predictive for decreased event-free survival, but not overall survival probability. CONCLUSIONS: These data support the hypothesis that inactivation of a tumor suppressor gene within 1p36.3 is associated with an increased risk for disease relapse.

Full Text

Duke Authors

Cited Authors

  • Maris, JM; Guo, C; Blake, D; White, PS; Hogarty, MD; Thompson, PM; Rajalingam, V; Gerbing, R; Stram, DO; Matthay, KK; Seeger, RC; Brodeur, GM

Published Date

  • January 2001

Published In

Volume / Issue

  • 36 / 1

Start / End Page

  • 32 - 36

PubMed ID

  • 11464900

Pubmed Central ID

  • 11464900

International Standard Serial Number (ISSN)

  • 0098-1532

Digital Object Identifier (DOI)

  • 10.1002/1096-911X(20010101)36:1<32::AID-MPO1009>3.0.CO;2-0

Conference Location

  • United States